BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Whittal A, Meregaglia M, Nicod E. The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. Patient 2021;14:485-503. [PMID: 33462774 DOI: 10.1007/s40271-020-00493-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kocher A, Simon M, Dwyer AA, Blatter C, Bogdanovic J, Künzler-Heule P, Villiger PM, Dan D, Distler O, Walker UA, Nicca D. Patient and healthcare professional eHealth literacy and needs for systemic sclerosis support: a mixed methods study. RMD Open 2021;7:e001783. [PMID: 34475248 DOI: 10.1136/rmdopen-2021-001783] [Reference Citation Analysis]
2 Ernst SK, Steinbeck V, Busse R, Pross C. Toward System-Wide Implementation of Patient-Reported Outcome Measures: A Framework for Countries, States, and Regions. Value in Health 2022. [DOI: 10.1016/j.jval.2022.04.1724] [Reference Citation Analysis]
3 Facey KM, Espin J, Kent E, Link A, Nicod E, O'Leary A, Xoxi E, van de Vijver I, Zaremba A, Benisheva T, Vagoras A, Upadhyaya S. Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel. Pharmacoeconomics 2021;39:1021-44. [PMID: 34231135 DOI: 10.1007/s40273-021-01050-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kerr K, Mckenna C, Heggarty S, Bailie C, Mcmullan J, Crowe A, Kilner J, Donnelly M, Boyle S, Rea G, Flanagan C, Mckee S, Mcknight AJ. A Formative Study of the Implementation of Whole Genome Sequencing in Northern Ireland. Genes 2022;13:1104. [DOI: 10.3390/genes13071104] [Reference Citation Analysis]
5 Bathen T, Johansen H, Strømme H, Velvin G. Experienced fatigue in people with rare disorders: a scoping review on characteristics of existing research. Orphanet J Rare Dis 2022;17:14. [PMID: 35012596 DOI: 10.1186/s13023-021-02169-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Yeh M, Fishman J, Sarda SP, Baver SB. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol 2022;101:251-63. [PMID: 34973099 DOI: 10.1007/s00277-021-04715-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]